###begin article-title 0
Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis
###end article-title 0
###begin p 1
###xml 198 199 198 199 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1404 1405 1364 1365 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
###xml 602 610 <span type="species:ncbi:9606">patients</span>
###xml 632 640 <span type="species:ncbi:9606">patients</span>
###xml 655 663 <span type="species:ncbi:9606">patients</span>
###xml 884 892 <span type="species:ncbi:9606">patients</span>
The aim of this study was to investigate the expressions of Toll-like receptor (TLR) 2, TLR4, TLR9, and their correlations with the expression of cytokines that are associated with activation of CD4+ T cells and inflammation including interferon gamma (IFNgamma), interleukin 4 (IL4), interleukin 17 (IL17), and tumor necrosis factor alpha (TNFalpha) in muscle tissues of patients with dermatomyositis (DM) and polymyositis (PM). The expressions of TLR2, TLR4, TLR9, IFNgamma, IL4, IL17, and TNFalpha were measured by real-time reverse transcription-polymerase chain reaction in muscle tissues from 14 patients with DM and PM (nine patients with DM, five patients with PM) and three controls. The expressions of TLR2, TLR4, and TLR9 were also localized with immunohistochemistry. The expression levels of TLR2, TLR4, TLR9, IFNgamma, IL4, IL17, and TNFalpha were significantly high in patients with DM and PM compared with those in the controls, and the expression levels of TLR4 and TLR9 had significant positive correlations with the expressions of IFNgamma, IL4, IL17, and TNFalpha. Immunohistochemistry showed that TLR2, TLR4, and TLR9 were expressed by infiltrating cells of perimysium in DM, whereas they were expressed by infiltrating cells of endomysium in PM. These results suggest that the involvement of TLR4 and TLR9 in immunopathogenesis of DM and PM might be connected with activation of CD4+ T cells.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 265 266 265 266 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 330 331 330 331 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 336 337 336 337 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 423 424 423 424 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 574 575 574 575 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 632 633 632 633 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 683 684 683 684 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
Dermatomyositis (DM) and polymyositis (PM) are chronic muscle disorders characterized by inflammatory infiltrate in the muscle tissue. DM and PM are clinically characterized by features of symmetric proximal muscle weakness associated with muscle cell destruction [1]. Previous studies have identified different proportions of CD4+, CD8+ T cells and macrophages with various localizations in DM and PM. In PM, cytotoxic CD8+ T cells and macrophages were detected surrounding and invading non-necrotic muscle fibers expressing major histocompatibility complex (MHC) class I [2]. In DM, perivascular infiltrates composed mainly of CD4+ T cells, B cells, and macrophages were observed [3].
###end p 4
###begin p 5
###xml 114 115 114 115 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 239 240 239 240 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 756 757 752 753 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 759 760 755 756 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1037 1038 1033 1034 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
The cytokine-driven differentiation of distinct lineages of effector and regulatory T cells (Tregs) from naive CD4+ T cell precursors is a hallmark of the adaptive immune system. T helper (Th) 1 and Th2 are the best understood effector CD4+ T cells generated during immune responses, with each subset characterized by distinct transcription factor activity and cytokine-secreting phenotype. Classically, Th1 cells produce interferon (IFN) gamma and mediate immune responses against intracellular bacteria, viruses, and tumor cells through the activation of macrophages and cytotoxic T cells. Th2 cells make mostly interleukin 4 (IL4), which stimulate humoral responses and are thought to have evolved to enhance resistance against extracellular parasites [4, 5]. In recent years, a distinct T-cell subset, termed Th17 cells, has also been identified and seems to play key roles in the activation of neutrophils and immunity to bacteria, particularly at mucosal surfaces. IL17, also termed IL17A, is the signature cytokine of Th17 cells [6].
###end p 5
###begin p 6
###xml 39 40 39 40 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 96 97 96 97 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 239 240 235 236 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 263 264 259 260 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
Recently reported data suggest that CD4+ T cells play roles in immunopathogenesis of DM and PM [7]. Identification of Th1 and Th17 cytokine (IFNgamma and IL17) producing cells from muscle tissue of DM and PM contributes to the roles of CD4+ T cells in DM and PM [8].
###end p 6
###begin p 7
###xml 675 676 671 672 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 473 481 <span type="species:ncbi:9606">patients</span>
Cytokines are potent mediators of a number of cell functions and are essential in coordinating inflammatory responses. They can be produced by a large variety of cells and exhibit pro-inflammatory as well as anti-inflammatory effects. Their key role in chronic inflammatory diseases has been well documented by the often strikingly good response to therapies targeting proinflammatory cytokines, one of the best examples being tumor necrosis factor (TNF) alpha blockade in patients with rheumatoid arthritis and Crohn's disease. Recent findings suggest cytokines as important key molecules in the pathogenic mechanisms of idiopathic inflammatory myopathies (IIMs), myositis [9].
###end p 7
###begin p 8
###xml 345 347 345 347 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 348 350 348 350 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 657 659 657 659 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 919 921 919 921 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 922 924 922 924 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
Toll-like receptors (TLRs) are primarily involved in the innate immune response to microbial pathogens through the recognition of conserved pathogen-associated molecular patterns. However, they also contribute to sterile inflammation by sensing "danger signals", the endogenous molecules that are generated during tissue damage or inflammation [10-13]. The activation of TLRs is an important bridge between innate and adaptive immunity by regulating the expression of co-stimulatory molecules on antigen-presenting cells that drive T-cell activation and by creating a cytokine milieu in which the differentiation of T cells into the desired subsets occurs [14]. It was known that activation of TLR4 and TLR9 is generally to induce a Th1 response in dendritic cells (DCs), and TLR2 might induce Th2-based immune response in experimental asthma, and activation of TLR4 also induces Th17 response through IL17 production [14-21].
###end p 8
###begin p 9
###xml 128 129 128 129 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 306 314 <span type="species:ncbi:9606">patients</span>
The aim of this study was to investigate the expression of TLR2, TLR4, TLR9, and cytokines that are related to activation of CD4+ T cells (Th1, Th2, and Th17 cells) and inflammations including IFNgamma, IL4, IL17, and TNFalpha, and to examine the connection of TLRs to these cytokines in muscle tissues of patients with DM and PM.
###end p 9
###begin p 10
###xml 169 177 <span type="species:ncbi:9606">patients</span>
Here, we demonstrate that the TLR4 and TLR9 expressions are significantly increased, and they are connected with the expressions of those cytokines in muscle tissues of patients with DM and PM.
###end p 10
###begin title 11
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 11
###begin title 12
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 12
###begin p 13
###xml 68 69 68 69 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 82 83 82 83 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 149 151 149 151 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 153 155 153 155 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 417 418 415 416 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 707 714 705 712 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 714 857 712 847 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="14">Clinical and laboratory characteristics and the expression of TLR2, TLR4, TLR9, IFN&#947;, IL4, IL17, and TNF&#945; in 14 patients with DM and PM</p>
###xml 714 857 712 847 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="14">Clinical and laboratory characteristics and the expression of TLR2, TLR4, TLR9, IFN&#947;, IL4, IL17, and TNF&#945; in 14 patients with DM and PM</p></caption>
###xml 857 874 847 864 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Patient/diagnosis</th>
###xml 874 877 864 867 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Sex</th>
###xml 877 880 867 870 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Age</th>
###xml 880 904 870 894 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Symptom duration, months</th>
###xml 904 912 894 902 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">CK (U/l)</th>
###xml 912 926 902 916 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Aldolase (U/l)</th>
###xml 926 936 916 926 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">ESR (mm/h)</th>
###xml 936 947 926 937 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">CRP (mg/dl)</th>
###xml 999 1000 989 990 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 947 1000 937 990 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" colspan="7">Relative mRNA expression levels compared to controls<sup>a</sup></th>
###xml 857 1000 847 990 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">Patient/diagnosis</th><th rowspan="2">Sex</th><th rowspan="2">Age</th><th rowspan="2">Symptom duration, months</th><th rowspan="2">CK (U/l)</th><th rowspan="2">Aldolase (U/l)</th><th rowspan="2">ESR (mm/h)</th><th rowspan="2">CRP (mg/dl)</th><th colspan="7">Relative mRNA expression levels compared to controls<sup>a</sup></th></tr>
###xml 1000 1004 990 994 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">TLR2</th>
###xml 1004 1008 994 998 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">TLR4</th>
###xml 1008 1012 998 1002 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">TLR9</th>
###xml 1012 1020 1002 1006 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IFN&#947;</th>
###xml 1020 1023 1006 1009 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IL4</th>
###xml 1023 1027 1009 1013 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IL17</th>
###xml 1027 1035 1013 1017 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">TNF&#945;</th>
###xml 1000 1035 990 1017 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th>TLR2</th><th>TLR4</th><th>TLR9</th><th>IFN&#947;</th><th>IL4</th><th>IL17</th><th>TNF&#945;</th></tr>
###xml 857 1035 847 1017 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">Patient/diagnosis</th><th rowspan="2">Sex</th><th rowspan="2">Age</th><th rowspan="2">Symptom duration, months</th><th rowspan="2">CK (U/l)</th><th rowspan="2">Aldolase (U/l)</th><th rowspan="2">ESR (mm/h)</th><th rowspan="2">CRP (mg/dl)</th><th colspan="7">Relative mRNA expression levels compared to controls<sup>a</sup></th></tr><tr><th>TLR2</th><th>TLR4</th><th>TLR9</th><th>IFN&#947;</th><th>IL4</th><th>IL17</th><th>TNF&#945;</th></tr></thead>
###xml 1035 1039 1017 1021 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1/DM</td>
###xml 1039 1040 1021 1022 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</td>
###xml 1040 1042 1022 1024 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">66</td>
###xml 1042 1043 1024 1025 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1043 1046 1025 1028 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">502</td>
###xml 1046 1050 1028 1032 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">10.1</td>
###xml 1050 1052 1032 1034 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">85</td>
###xml 1052 1056 1034 1038 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3.41</td>
###xml 1056 1060 1038 1042 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">16.4</td>
###xml 1060 1064 1042 1046 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">48.4</td>
###xml 1064 1068 1046 1050 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">11.2</td>
###xml 1068 1071 1050 1053 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">587</td>
###xml 1071 1074 1053 1056 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">9.4</td>
###xml 1074 1076 1056 1058 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">40</td>
###xml 1076 1079 1058 1061 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">9.5</td>
###xml 1035 1079 1017 1061 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>1/DM</td><td>F</td><td>66</td><td>1</td><td>502</td><td>10.1</td><td>85</td><td>3.41</td><td>16.4</td><td>48.4</td><td>11.2</td><td>587</td><td>9.4</td><td>40</td><td>9.5</td></tr>
###xml 1079 1083 1061 1065 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2/DM</td>
###xml 1083 1084 1065 1066 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">M</td>
###xml 1084 1086 1066 1068 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">36</td>
###xml 1086 1087 1068 1069 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</td>
###xml 1087 1092 1069 1074 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2,815</td>
###xml 1092 1096 1074 1078 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">46.1</td>
###xml 1096 1098 1078 1080 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">75</td>
###xml 1098 1101 1080 1083 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.9</td>
###xml 1101 1105 1083 1087 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18.6</td>
###xml 1105 1108 1087 1090 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">140</td>
###xml 1108 1112 1090 1094 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">15.1</td>
###xml 1112 1117 1094 1099 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1,430</td>
###xml 1117 1121 1099 1103 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">23.3</td>
###xml 1121 1123 1103 1105 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">68</td>
###xml 1123 1125 1105 1107 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">27</td>
###xml 1079 1125 1061 1107 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>2/DM</td><td>M</td><td>36</td><td>3</td><td>2,815</td><td>46.1</td><td>75</td><td>0.9</td><td>18.6</td><td>140</td><td>15.1</td><td>1,430</td><td>23.3</td><td>68</td><td>27</td></tr>
###xml 1125 1129 1107 1111 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3/DM</td>
###xml 1129 1130 1111 1112 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">M</td>
###xml 1130 1132 1112 1114 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">39</td>
###xml 1132 1133 1114 1115 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</td>
###xml 1133 1138 1115 1120 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1,163</td>
###xml 1138 1141 1120 1123 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">7.1</td>
###xml 1141 1143 1123 1125 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">85</td>
###xml 1143 1146 1125 1128 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.5</td>
###xml 1146 1150 1128 1132 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">25.1</td>
###xml 1150 1153 1132 1135 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">164</td>
###xml 1153 1156 1135 1138 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">5.6</td>
###xml 1156 1159 1138 1141 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">278</td>
###xml 1159 1162 1141 1144 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">4.6</td>
###xml 1162 1164 1144 1146 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18</td>
###xml 1164 1167 1146 1149 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3.7</td>
###xml 1125 1167 1107 1149 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>3/DM</td><td>M</td><td>39</td><td>2</td><td>1,163</td><td>7.1</td><td>85</td><td>0.5</td><td>25.1</td><td>164</td><td>5.6</td><td>278</td><td>4.6</td><td>18</td><td>3.7</td></tr>
###xml 1167 1171 1149 1153 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">4/DM</td>
###xml 1171 1172 1153 1154 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">M</td>
###xml 1172 1174 1154 1156 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">37</td>
###xml 1174 1176 1156 1158 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">12</td>
###xml 1176 1178 1158 1160 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">70</td>
###xml 1178 1181 1160 1163 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">5.7</td>
###xml 1181 1183 1163 1165 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">78</td>
###xml 1183 1186 1165 1168 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.5</td>
###xml 1186 1190 1168 1172 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">15.1</td>
###xml 1190 1193 1172 1175 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">106</td>
###xml 1193 1197 1175 1179 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">11.6</td>
###xml 1197 1200 1179 1182 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">484</td>
###xml 1200 1203 1182 1185 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">6.7</td>
###xml 1203 1205 1185 1187 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">27</td>
###xml 1205 1209 1187 1191 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">13.9</td>
###xml 1167 1209 1149 1191 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>4/DM</td><td>M</td><td>37</td><td>12</td><td>70</td><td>5.7</td><td>78</td><td>0.5</td><td>15.1</td><td>106</td><td>11.6</td><td>484</td><td>6.7</td><td>27</td><td>13.9</td></tr>
###xml 1209 1213 1191 1195 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">5/DM</td>
###xml 1213 1214 1195 1196 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">M</td>
###xml 1214 1216 1196 1198 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">58</td>
###xml 1216 1217 1198 1199 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1217 1222 1199 1204 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3,006</td>
###xml 1222 1225 1204 1207 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8.4</td>
###xml 1225 1227 1207 1209 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">13</td>
###xml 1227 1230 1209 1212 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.5</td>
###xml 1230 1234 1212 1216 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">48.1</td>
###xml 1234 1238 1216 1220 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">60.8</td>
###xml 1238 1241 1220 1223 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">4.6</td>
###xml 1241 1244 1223 1226 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">273</td>
###xml 1244 1247 1226 1229 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.8</td>
###xml 1247 1248 1229 1230 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">9</td>
###xml 1248 1251 1230 1233 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">4.8</td>
###xml 1209 1251 1191 1233 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>5/DM</td><td>M</td><td>58</td><td>1</td><td>3,006</td><td>8.4</td><td>13</td><td>0.5</td><td>48.1</td><td>60.8</td><td>4.6</td><td>273</td><td>1.8</td><td>9</td><td>4.8</td></tr>
###xml 1251 1255 1233 1237 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">6/DM</td>
###xml 1255 1256 1237 1238 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">M</td>
###xml 1256 1258 1238 1240 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">37</td>
###xml 1258 1259 1240 1241 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</td>
###xml 1259 1265 1241 1247 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">14,139</td>
###xml 1265 1269 1247 1251 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">36.7</td>
###xml 1269 1271 1251 1253 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">73</td>
###xml 1271 1274 1253 1256 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2.8</td>
###xml 1274 1278 1256 1260 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">57.1</td>
###xml 1278 1280 1260 1262 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">81</td>
###xml 1280 1283 1262 1265 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">6.0</td>
###xml 1283 1286 1265 1268 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">462</td>
###xml 1286 1289 1268 1271 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">5.3</td>
###xml 1289 1291 1271 1273 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">19</td>
###xml 1291 1295 1273 1277 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">21.7</td>
###xml 1251 1295 1233 1277 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>6/DM</td><td>M</td><td>37</td><td>2</td><td>14,139</td><td>36.7</td><td>73</td><td>2.8</td><td>57.1</td><td>81</td><td>6.0</td><td>462</td><td>5.3</td><td>19</td><td>21.7</td></tr>
###xml 1295 1299 1277 1281 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">7/DM</td>
###xml 1299 1300 1281 1282 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">M</td>
###xml 1300 1302 1282 1284 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">55</td>
###xml 1302 1303 1284 1285 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1303 1308 1285 1290 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3,034</td>
###xml 1308 1312 1290 1294 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">21.9</td>
###xml 1312 1314 1294 1296 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">24</td>
###xml 1314 1317 1296 1299 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2.3</td>
###xml 1317 1321 1299 1303 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">13.1</td>
###xml 1321 1324 1303 1306 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">153</td>
###xml 1324 1328 1306 1310 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">37.2</td>
###xml 1328 1331 1310 1313 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">885</td>
###xml 1331 1335 1313 1317 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">15.3</td>
###xml 1335 1337 1317 1319 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">62</td>
###xml 1337 1341 1319 1323 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">17.1</td>
###xml 1295 1341 1277 1323 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>7/DM</td><td>M</td><td>55</td><td>1</td><td>3,034</td><td>21.9</td><td>24</td><td>2.3</td><td>13.1</td><td>153</td><td>37.2</td><td>885</td><td>15.3</td><td>62</td><td>17.1</td></tr>
###xml 1341 1345 1323 1327 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8/DM</td>
###xml 1345 1346 1327 1328 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</td>
###xml 1346 1348 1328 1330 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">30</td>
###xml 1348 1349 1330 1331 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 1349 1354 1331 1336 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">6,000</td>
###xml 1354 1358 1336 1340 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">54.3</td>
###xml 1358 1360 1340 1342 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">14</td>
###xml 1360 1363 1342 1345 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.1</td>
###xml 1363 1367 1345 1349 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">69.8</td>
###xml 1367 1370 1349 1352 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">232</td>
###xml 1370 1374 1352 1356 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">26.3</td>
###xml 1374 1379 1356 1361 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2,760</td>
###xml 1379 1383 1361 1365 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">23.7</td>
###xml 1383 1386 1365 1368 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">100</td>
###xml 1386 1390 1368 1372 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">20.2</td>
###xml 1341 1390 1323 1372 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>8/DM</td><td>F</td><td>30</td><td>6</td><td>6,000</td><td>54.3</td><td>14</td><td>0.1</td><td>69.8</td><td>232</td><td>26.3</td><td>2,760</td><td>23.7</td><td>100</td><td>20.2</td></tr>
###xml 1390 1394 1372 1376 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">9/DM</td>
###xml 1394 1395 1376 1377 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</td>
###xml 1395 1397 1377 1379 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18</td>
###xml 1397 1398 1379 1380 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</td>
###xml 1398 1401 1380 1383 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">668</td>
###xml 1401 1405 1383 1387 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">16.5</td>
###xml 1405 1407 1387 1389 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">52</td>
###xml 1407 1410 1389 1392 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.1</td>
###xml 1410 1414 1392 1396 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">28.7</td>
###xml 1414 1417 1396 1399 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">297</td>
###xml 1417 1421 1399 1403 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">34.4</td>
###xml 1421 1426 1403 1408 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3,140</td>
###xml 1426 1430 1408 1412 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">71.0</td>
###xml 1430 1433 1412 1415 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">122</td>
###xml 1433 1437 1415 1419 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">82.5</td>
###xml 1390 1437 1372 1419 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>9/DM</td><td>F</td><td>18</td><td>3</td><td>668</td><td>16.5</td><td>52</td><td>0.1</td><td>28.7</td><td>297</td><td>34.4</td><td>3,140</td><td>71.0</td><td>122</td><td>82.5</td></tr>
###xml 1437 1442 1419 1424 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">10/PM</td>
###xml 1442 1443 1424 1425 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</td>
###xml 1443 1445 1425 1427 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">47</td>
###xml 1445 1446 1427 1428 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</td>
###xml 1446 1452 1428 1434 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">10,994</td>
###xml 1452 1457 1434 1439 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">109.5</td>
###xml 1457 1459 1439 1441 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">37</td>
###xml 1459 1462 1441 1444 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.4</td>
###xml 1462 1466 1444 1448 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18.6</td>
###xml 1466 1469 1448 1451 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">169</td>
###xml 1469 1473 1451 1455 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">14.8</td>
###xml 1473 1476 1455 1458 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">674</td>
###xml 1476 1480 1458 1462 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">15.9</td>
###xml 1480 1482 1462 1464 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">75</td>
###xml 1482 1486 1464 1468 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">31.3</td>
###xml 1437 1486 1419 1468 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>10/PM</td><td>F</td><td>47</td><td>2</td><td>10,994</td><td>109.5</td><td>37</td><td>0.4</td><td>18.6</td><td>169</td><td>14.8</td><td>674</td><td>15.9</td><td>75</td><td>31.3</td></tr>
###xml 1486 1491 1468 1473 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">11/PM</td>
###xml 1491 1492 1473 1474 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">M</td>
###xml 1492 1494 1474 1476 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">22</td>
###xml 1494 1495 1476 1477 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</td>
###xml 1495 1497 1477 1479 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">32</td>
###xml 1497 1500 1479 1482 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">6.9</td>
###xml 1500 1502 1482 1484 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">26</td>
###xml 1502 1505 1484 1487 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.3</td>
###xml 1505 1509 1487 1491 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">16.1</td>
###xml 1509 1512 1491 1494 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">149</td>
###xml 1512 1516 1494 1498 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">10.0</td>
###xml 1516 1519 1498 1501 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">382</td>
###xml 1519 1522 1501 1504 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">4.7</td>
###xml 1522 1524 1504 1506 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">22</td>
###xml 1524 1527 1506 1509 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8.2</td>
###xml 1486 1527 1468 1509 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>11/PM</td><td>M</td><td>22</td><td>3</td><td>32</td><td>6.9</td><td>26</td><td>1.3</td><td>16.1</td><td>149</td><td>10.0</td><td>382</td><td>4.7</td><td>22</td><td>8.2</td></tr>
###xml 1527 1532 1509 1514 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">12/PM</td>
###xml 1532 1533 1514 1515 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</td>
###xml 1533 1535 1515 1517 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">59</td>
###xml 1535 1536 1517 1518 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1536 1541 1518 1523 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2,207</td>
###xml 1541 1543 1523 1525 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">44</td>
###xml 1543 1546 1525 1528 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">108</td>
###xml 1546 1549 1528 1531 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.8</td>
###xml 1549 1553 1531 1535 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">50.3</td>
###xml 1553 1556 1535 1538 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">228</td>
###xml 1556 1560 1538 1542 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">35.2</td>
###xml 1560 1565 1542 1547 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1,830</td>
###xml 1565 1569 1547 1551 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">22.6</td>
###xml 1569 1572 1551 1554 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">139</td>
###xml 1572 1576 1554 1558 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">23.5</td>
###xml 1527 1576 1509 1558 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>12/PM</td><td>F</td><td>59</td><td>1</td><td>2,207</td><td>44</td><td>108</td><td>1.8</td><td>50.3</td><td>228</td><td>35.2</td><td>1,830</td><td>22.6</td><td>139</td><td>23.5</td></tr>
###xml 1576 1581 1558 1563 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">13/PM</td>
###xml 1581 1582 1563 1564 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</td>
###xml 1582 1584 1564 1566 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">33</td>
###xml 1584 1585 1566 1567 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">7</td>
###xml 1585 1590 1567 1572 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2,743</td>
###xml 1590 1592 1572 1574 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">64</td>
###xml 1592 1594 1574 1576 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">50</td>
###xml 1594 1597 1576 1579 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.0</td>
###xml 1597 1601 1579 1583 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">39.5</td>
###xml 1601 1604 1583 1586 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">444</td>
###xml 1604 1608 1586 1590 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">44.0</td>
###xml 1608 1613 1590 1595 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2,180</td>
###xml 1613 1617 1595 1599 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">47.1</td>
###xml 1617 1620 1599 1602 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">218</td>
###xml 1620 1624 1602 1606 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">50.5</td>
###xml 1576 1624 1558 1606 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>13/PM</td><td>F</td><td>33</td><td>7</td><td>2,743</td><td>64</td><td>50</td><td>1.0</td><td>39.5</td><td>444</td><td>44.0</td><td>2,180</td><td>47.1</td><td>218</td><td>50.5</td></tr>
###xml 1624 1629 1606 1611 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">14/PM</td>
###xml 1629 1630 1611 1612 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</td>
###xml 1630 1632 1612 1614 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">48</td>
###xml 1632 1633 1614 1615 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1633 1638 1615 1620 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1,820</td>
###xml 1638 1642 1620 1624 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">44.8</td>
###xml 1642 1644 1624 1626 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">19</td>
###xml 1644 1647 1626 1629 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.6</td>
###xml 1647 1651 1629 1633 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">35.9</td>
###xml 1651 1654 1633 1636 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">108</td>
###xml 1654 1657 1636 1639 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">5.2</td>
###xml 1657 1660 1639 1642 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">334</td>
###xml 1660 1663 1642 1645 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3.4</td>
###xml 1663 1665 1645 1647 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">11</td>
###xml 1665 1668 1647 1650 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3.2</td>
###xml 1624 1668 1606 1650 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>14/PM</td><td>F</td><td>48</td><td>1</td><td>1,820</td><td>44.8</td><td>19</td><td>0.6</td><td>35.9</td><td>108</td><td>5.2</td><td>334</td><td>3.4</td><td>11</td><td>3.2</td></tr>
###xml 1668 1679 1650 1661 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">DM/PM (9/5)</td>
###xml 1679 1688 1661 1670 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">M/F (7/7)</td>
###xml 1688 1697 1670 1677 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">41&#8201;&#177;&#8201;14</td>
###xml 1697 1708 1677 1686 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3.2&#8201;&#177;&#8201;3.1</td>
###xml 1708 1723 1686 1699 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3,510&#8201;&#177;&#8201;4,180</td>
###xml 1723 1732 1699 1706 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">34&#8201;&#177;&#8201;30</td>
###xml 1732 1741 1706 1713 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">53&#8201;&#177;&#8201;31</td>
###xml 1741 1752 1713 1722 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.2&#8201;&#177;&#8201;1.0</td>
###xml 1752 1765 1722 1733 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">32.3&#8201;&#177;&#8201;18.1</td>
###xml 1765 1780 1733 1746 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">170.0&#8201;&#177;&#8201;104.8</td>
###xml 1780 1793 1746 1757 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18.6&#8201;&#177;&#8201;13.8</td>
###xml 1793 1810 1757 1772 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1,121.3&#8201;&#177;&#8201;978.9</td>
###xml 1810 1823 1772 1783 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18.1&#8201;&#177;&#8201;19.5</td>
###xml 1823 1836 1783 1794 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">66.4&#8201;&#177;&#8201;60.6</td>
###xml 1836 1849 1794 1805 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">22.7&#8201;&#177;&#8201;21.5</td>
###xml 1668 1849 1650 1805 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>DM/PM (9/5)</td><td>M/F (7/7)</td><td>41&#8201;&#177;&#8201;14</td><td>3.2&#8201;&#177;&#8201;3.1</td><td>3,510&#8201;&#177;&#8201;4,180</td><td>34&#8201;&#177;&#8201;30</td><td>53&#8201;&#177;&#8201;31</td><td>1.2&#8201;&#177;&#8201;1.0</td><td>32.3&#8201;&#177;&#8201;18.1</td><td>170.0&#8201;&#177;&#8201;104.8</td><td>18.6&#8201;&#177;&#8201;13.8</td><td>1,121.3&#8201;&#177;&#8201;978.9</td><td>18.1&#8201;&#177;&#8201;19.5</td><td>66.4&#8201;&#177;&#8201;60.6</td><td>22.7&#8201;&#177;&#8201;21.5</td></tr>
###xml 1035 1849 1017 1805 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>1/DM</td><td>F</td><td>66</td><td>1</td><td>502</td><td>10.1</td><td>85</td><td>3.41</td><td>16.4</td><td>48.4</td><td>11.2</td><td>587</td><td>9.4</td><td>40</td><td>9.5</td></tr><tr><td>2/DM</td><td>M</td><td>36</td><td>3</td><td>2,815</td><td>46.1</td><td>75</td><td>0.9</td><td>18.6</td><td>140</td><td>15.1</td><td>1,430</td><td>23.3</td><td>68</td><td>27</td></tr><tr><td>3/DM</td><td>M</td><td>39</td><td>2</td><td>1,163</td><td>7.1</td><td>85</td><td>0.5</td><td>25.1</td><td>164</td><td>5.6</td><td>278</td><td>4.6</td><td>18</td><td>3.7</td></tr><tr><td>4/DM</td><td>M</td><td>37</td><td>12</td><td>70</td><td>5.7</td><td>78</td><td>0.5</td><td>15.1</td><td>106</td><td>11.6</td><td>484</td><td>6.7</td><td>27</td><td>13.9</td></tr><tr><td>5/DM</td><td>M</td><td>58</td><td>1</td><td>3,006</td><td>8.4</td><td>13</td><td>0.5</td><td>48.1</td><td>60.8</td><td>4.6</td><td>273</td><td>1.8</td><td>9</td><td>4.8</td></tr><tr><td>6/DM</td><td>M</td><td>37</td><td>2</td><td>14,139</td><td>36.7</td><td>73</td><td>2.8</td><td>57.1</td><td>81</td><td>6.0</td><td>462</td><td>5.3</td><td>19</td><td>21.7</td></tr><tr><td>7/DM</td><td>M</td><td>55</td><td>1</td><td>3,034</td><td>21.9</td><td>24</td><td>2.3</td><td>13.1</td><td>153</td><td>37.2</td><td>885</td><td>15.3</td><td>62</td><td>17.1</td></tr><tr><td>8/DM</td><td>F</td><td>30</td><td>6</td><td>6,000</td><td>54.3</td><td>14</td><td>0.1</td><td>69.8</td><td>232</td><td>26.3</td><td>2,760</td><td>23.7</td><td>100</td><td>20.2</td></tr><tr><td>9/DM</td><td>F</td><td>18</td><td>3</td><td>668</td><td>16.5</td><td>52</td><td>0.1</td><td>28.7</td><td>297</td><td>34.4</td><td>3,140</td><td>71.0</td><td>122</td><td>82.5</td></tr><tr><td>10/PM</td><td>F</td><td>47</td><td>2</td><td>10,994</td><td>109.5</td><td>37</td><td>0.4</td><td>18.6</td><td>169</td><td>14.8</td><td>674</td><td>15.9</td><td>75</td><td>31.3</td></tr><tr><td>11/PM</td><td>M</td><td>22</td><td>3</td><td>32</td><td>6.9</td><td>26</td><td>1.3</td><td>16.1</td><td>149</td><td>10.0</td><td>382</td><td>4.7</td><td>22</td><td>8.2</td></tr><tr><td>12/PM</td><td>F</td><td>59</td><td>1</td><td>2,207</td><td>44</td><td>108</td><td>1.8</td><td>50.3</td><td>228</td><td>35.2</td><td>1,830</td><td>22.6</td><td>139</td><td>23.5</td></tr><tr><td>13/PM</td><td>F</td><td>33</td><td>7</td><td>2,743</td><td>64</td><td>50</td><td>1.0</td><td>39.5</td><td>444</td><td>44.0</td><td>2,180</td><td>47.1</td><td>218</td><td>50.5</td></tr><tr><td>14/PM</td><td>F</td><td>48</td><td>1</td><td>1,820</td><td>44.8</td><td>19</td><td>0.6</td><td>35.9</td><td>108</td><td>5.2</td><td>334</td><td>3.4</td><td>11</td><td>3.2</td></tr><tr><td>DM/PM (9/5)</td><td>M/F (7/7)</td><td>41&#8201;&#177;&#8201;14</td><td>3.2&#8201;&#177;&#8201;3.1</td><td>3,510&#8201;&#177;&#8201;4,180</td><td>34&#8201;&#177;&#8201;30</td><td>53&#8201;&#177;&#8201;31</td><td>1.2&#8201;&#177;&#8201;1.0</td><td>32.3&#8201;&#177;&#8201;18.1</td><td>170.0&#8201;&#177;&#8201;104.8</td><td>18.6&#8201;&#177;&#8201;13.8</td><td>1,121.3&#8201;&#177;&#8201;978.9</td><td>18.1&#8201;&#177;&#8201;19.5</td><td>66.4&#8201;&#177;&#8201;60.6</td><td>22.7&#8201;&#177;&#8201;21.5</td></tr></tbody>
###xml 857 1849 847 1805 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">Patient/diagnosis</th><th rowspan="2">Sex</th><th rowspan="2">Age</th><th rowspan="2">Symptom duration, months</th><th rowspan="2">CK (U/l)</th><th rowspan="2">Aldolase (U/l)</th><th rowspan="2">ESR (mm/h)</th><th rowspan="2">CRP (mg/dl)</th><th colspan="7">Relative mRNA expression levels compared to controls<sup>a</sup></th></tr><tr><th>TLR2</th><th>TLR4</th><th>TLR9</th><th>IFN&#947;</th><th>IL4</th><th>IL17</th><th>TNF&#945;</th></tr></thead><tbody><tr><td>1/DM</td><td>F</td><td>66</td><td>1</td><td>502</td><td>10.1</td><td>85</td><td>3.41</td><td>16.4</td><td>48.4</td><td>11.2</td><td>587</td><td>9.4</td><td>40</td><td>9.5</td></tr><tr><td>2/DM</td><td>M</td><td>36</td><td>3</td><td>2,815</td><td>46.1</td><td>75</td><td>0.9</td><td>18.6</td><td>140</td><td>15.1</td><td>1,430</td><td>23.3</td><td>68</td><td>27</td></tr><tr><td>3/DM</td><td>M</td><td>39</td><td>2</td><td>1,163</td><td>7.1</td><td>85</td><td>0.5</td><td>25.1</td><td>164</td><td>5.6</td><td>278</td><td>4.6</td><td>18</td><td>3.7</td></tr><tr><td>4/DM</td><td>M</td><td>37</td><td>12</td><td>70</td><td>5.7</td><td>78</td><td>0.5</td><td>15.1</td><td>106</td><td>11.6</td><td>484</td><td>6.7</td><td>27</td><td>13.9</td></tr><tr><td>5/DM</td><td>M</td><td>58</td><td>1</td><td>3,006</td><td>8.4</td><td>13</td><td>0.5</td><td>48.1</td><td>60.8</td><td>4.6</td><td>273</td><td>1.8</td><td>9</td><td>4.8</td></tr><tr><td>6/DM</td><td>M</td><td>37</td><td>2</td><td>14,139</td><td>36.7</td><td>73</td><td>2.8</td><td>57.1</td><td>81</td><td>6.0</td><td>462</td><td>5.3</td><td>19</td><td>21.7</td></tr><tr><td>7/DM</td><td>M</td><td>55</td><td>1</td><td>3,034</td><td>21.9</td><td>24</td><td>2.3</td><td>13.1</td><td>153</td><td>37.2</td><td>885</td><td>15.3</td><td>62</td><td>17.1</td></tr><tr><td>8/DM</td><td>F</td><td>30</td><td>6</td><td>6,000</td><td>54.3</td><td>14</td><td>0.1</td><td>69.8</td><td>232</td><td>26.3</td><td>2,760</td><td>23.7</td><td>100</td><td>20.2</td></tr><tr><td>9/DM</td><td>F</td><td>18</td><td>3</td><td>668</td><td>16.5</td><td>52</td><td>0.1</td><td>28.7</td><td>297</td><td>34.4</td><td>3,140</td><td>71.0</td><td>122</td><td>82.5</td></tr><tr><td>10/PM</td><td>F</td><td>47</td><td>2</td><td>10,994</td><td>109.5</td><td>37</td><td>0.4</td><td>18.6</td><td>169</td><td>14.8</td><td>674</td><td>15.9</td><td>75</td><td>31.3</td></tr><tr><td>11/PM</td><td>M</td><td>22</td><td>3</td><td>32</td><td>6.9</td><td>26</td><td>1.3</td><td>16.1</td><td>149</td><td>10.0</td><td>382</td><td>4.7</td><td>22</td><td>8.2</td></tr><tr><td>12/PM</td><td>F</td><td>59</td><td>1</td><td>2,207</td><td>44</td><td>108</td><td>1.8</td><td>50.3</td><td>228</td><td>35.2</td><td>1,830</td><td>22.6</td><td>139</td><td>23.5</td></tr><tr><td>13/PM</td><td>F</td><td>33</td><td>7</td><td>2,743</td><td>64</td><td>50</td><td>1.0</td><td>39.5</td><td>444</td><td>44.0</td><td>2,180</td><td>47.1</td><td>218</td><td>50.5</td></tr><tr><td>14/PM</td><td>F</td><td>48</td><td>1</td><td>1,820</td><td>44.8</td><td>19</td><td>0.6</td><td>35.9</td><td>108</td><td>5.2</td><td>334</td><td>3.4</td><td>11</td><td>3.2</td></tr><tr><td>DM/PM (9/5)</td><td>M/F (7/7)</td><td>41&#8201;&#177;&#8201;14</td><td>3.2&#8201;&#177;&#8201;3.1</td><td>3,510&#8201;&#177;&#8201;4,180</td><td>34&#8201;&#177;&#8201;30</td><td>53&#8201;&#177;&#8201;31</td><td>1.2&#8201;&#177;&#8201;1.0</td><td>32.3&#8201;&#177;&#8201;18.1</td><td>170.0&#8201;&#177;&#8201;104.8</td><td>18.6&#8201;&#177;&#8201;13.8</td><td>1,121.3&#8201;&#177;&#8201;978.9</td><td>18.1&#8201;&#177;&#8201;19.5</td><td>66.4&#8201;&#177;&#8201;60.6</td><td>22.7&#8201;&#177;&#8201;21.5</td></tr></tbody></table>
###xml 1849 1850 1805 1806 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1849 2065 1805 2021 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="15"><sup>a</sup>The mRNA expressions were showed by relative levels compared to controls. Muscle tissue sections from three patients with non-specific muscle manifestations but normal histological findings were used as the controls</p>
###xml 1849 2065 1805 2021 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="15"><sup>a</sup>The mRNA expressions were showed by relative levels compared to controls. Muscle tissue sections from three patients with non-specific muscle manifestations but normal histological findings were used as the controls</p></table-wrap-foot>
###xml 707 2065 705 2021 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="14">Clinical and laboratory characteristics and the expression of TLR2, TLR4, TLR9, IFN&#947;, IL4, IL17, and TNF&#945; in 14 patients with DM and PM</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Patient/diagnosis</th><th rowspan="2">Sex</th><th rowspan="2">Age</th><th rowspan="2">Symptom duration, months</th><th rowspan="2">CK (U/l)</th><th rowspan="2">Aldolase (U/l)</th><th rowspan="2">ESR (mm/h)</th><th rowspan="2">CRP (mg/dl)</th><th colspan="7">Relative mRNA expression levels compared to controls<sup>a</sup></th></tr><tr><th>TLR2</th><th>TLR4</th><th>TLR9</th><th>IFN&#947;</th><th>IL4</th><th>IL17</th><th>TNF&#945;</th></tr></thead><tbody><tr><td>1/DM</td><td>F</td><td>66</td><td>1</td><td>502</td><td>10.1</td><td>85</td><td>3.41</td><td>16.4</td><td>48.4</td><td>11.2</td><td>587</td><td>9.4</td><td>40</td><td>9.5</td></tr><tr><td>2/DM</td><td>M</td><td>36</td><td>3</td><td>2,815</td><td>46.1</td><td>75</td><td>0.9</td><td>18.6</td><td>140</td><td>15.1</td><td>1,430</td><td>23.3</td><td>68</td><td>27</td></tr><tr><td>3/DM</td><td>M</td><td>39</td><td>2</td><td>1,163</td><td>7.1</td><td>85</td><td>0.5</td><td>25.1</td><td>164</td><td>5.6</td><td>278</td><td>4.6</td><td>18</td><td>3.7</td></tr><tr><td>4/DM</td><td>M</td><td>37</td><td>12</td><td>70</td><td>5.7</td><td>78</td><td>0.5</td><td>15.1</td><td>106</td><td>11.6</td><td>484</td><td>6.7</td><td>27</td><td>13.9</td></tr><tr><td>5/DM</td><td>M</td><td>58</td><td>1</td><td>3,006</td><td>8.4</td><td>13</td><td>0.5</td><td>48.1</td><td>60.8</td><td>4.6</td><td>273</td><td>1.8</td><td>9</td><td>4.8</td></tr><tr><td>6/DM</td><td>M</td><td>37</td><td>2</td><td>14,139</td><td>36.7</td><td>73</td><td>2.8</td><td>57.1</td><td>81</td><td>6.0</td><td>462</td><td>5.3</td><td>19</td><td>21.7</td></tr><tr><td>7/DM</td><td>M</td><td>55</td><td>1</td><td>3,034</td><td>21.9</td><td>24</td><td>2.3</td><td>13.1</td><td>153</td><td>37.2</td><td>885</td><td>15.3</td><td>62</td><td>17.1</td></tr><tr><td>8/DM</td><td>F</td><td>30</td><td>6</td><td>6,000</td><td>54.3</td><td>14</td><td>0.1</td><td>69.8</td><td>232</td><td>26.3</td><td>2,760</td><td>23.7</td><td>100</td><td>20.2</td></tr><tr><td>9/DM</td><td>F</td><td>18</td><td>3</td><td>668</td><td>16.5</td><td>52</td><td>0.1</td><td>28.7</td><td>297</td><td>34.4</td><td>3,140</td><td>71.0</td><td>122</td><td>82.5</td></tr><tr><td>10/PM</td><td>F</td><td>47</td><td>2</td><td>10,994</td><td>109.5</td><td>37</td><td>0.4</td><td>18.6</td><td>169</td><td>14.8</td><td>674</td><td>15.9</td><td>75</td><td>31.3</td></tr><tr><td>11/PM</td><td>M</td><td>22</td><td>3</td><td>32</td><td>6.9</td><td>26</td><td>1.3</td><td>16.1</td><td>149</td><td>10.0</td><td>382</td><td>4.7</td><td>22</td><td>8.2</td></tr><tr><td>12/PM</td><td>F</td><td>59</td><td>1</td><td>2,207</td><td>44</td><td>108</td><td>1.8</td><td>50.3</td><td>228</td><td>35.2</td><td>1,830</td><td>22.6</td><td>139</td><td>23.5</td></tr><tr><td>13/PM</td><td>F</td><td>33</td><td>7</td><td>2,743</td><td>64</td><td>50</td><td>1.0</td><td>39.5</td><td>444</td><td>44.0</td><td>2,180</td><td>47.1</td><td>218</td><td>50.5</td></tr><tr><td>14/PM</td><td>F</td><td>48</td><td>1</td><td>1,820</td><td>44.8</td><td>19</td><td>0.6</td><td>35.9</td><td>108</td><td>5.2</td><td>334</td><td>3.4</td><td>11</td><td>3.2</td></tr><tr><td>DM/PM (9/5)</td><td>M/F (7/7)</td><td>41&#8201;&#177;&#8201;14</td><td>3.2&#8201;&#177;&#8201;3.1</td><td>3,510&#8201;&#177;&#8201;4,180</td><td>34&#8201;&#177;&#8201;30</td><td>53&#8201;&#177;&#8201;31</td><td>1.2&#8201;&#177;&#8201;1.0</td><td>32.3&#8201;&#177;&#8201;18.1</td><td>170.0&#8201;&#177;&#8201;104.8</td><td>18.6&#8201;&#177;&#8201;13.8</td><td>1,121.3&#8201;&#177;&#8201;978.9</td><td>18.1&#8201;&#177;&#8201;19.5</td><td>66.4&#8201;&#177;&#8201;60.6</td><td>22.7&#8201;&#177;&#8201;21.5</td></tr></tbody></table><table-wrap-foot><p textid="15"><sup>a</sup>The mRNA expressions were showed by relative levels compared to controls. Muscle tissue sections from three patients with non-specific muscle manifestations but normal histological findings were used as the controls</p></table-wrap-foot></table-wrap>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 208 213 <span type="species:ncbi:9606">women</span>
###xml 229 232 <span type="species:ncbi:9606">men</span>
###xml 381 388 <span type="species:ncbi:9606">Patient</span>
###xml 454 462 <span type="species:ncbi:9606">patients</span>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
###xml 834 842 <span type="species:ncbi:9606">patients</span>
###xml 1958 1966 <span type="species:ncbi:9606">patients</span>
Muscle biopsy samples from patients newly diagnosed with active DM (n = 9) or PM (n = 5), according to the classification system of Bohan and Peter [22, 23], were evaluated in this study. Seven patients were women and seven were men. The time from symptom onset to diagnosis was 1-12 months, and they had not been treated. The mean age at diagnosis was 41 years (41 +/- 14 years). Patient data are presented in Table 1. Muscle tissue sections from three patients with non-specific muscle manifestations but normal histological findings were used as the controls. All patients and controls gave their informed consent, and the local ethics committee at Pusan National University Hospital approved the study. Table 1Clinical and laboratory characteristics and the expression of TLR2, TLR4, TLR9, IFNgamma, IL4, IL17, and TNFalpha in 14 patients with DM and PMPatient/diagnosisSexAgeSymptom duration, monthsCK (U/l)Aldolase (U/l)ESR (mm/h)CRP (mg/dl)Relative mRNA expression levels compared to controlsaTLR2TLR4TLR9IFNgammaIL4IL17TNFalpha1/DMF66150210.1853.4116.448.411.25879.4409.52/DMM3632,81546.1750.918.614015.11,43023.368273/DMM3921,1637.1850.525.11645.62784.6183.74/DMM3712705.7780.515.110611.64846.72713.95/DMM5813,0068.4130.548.160.84.62731.894.86/DMM37214,13936.7732.857.1816.04625.31921.77/DMM5513,03421.9242.313.115337.288515.36217.18/DMF3066,00054.3140.169.823226.32,76023.710020.29/DMF18366816.5520.128.729734.43,14071.012282.510/PMF47210,994109.5370.418.616914.867415.97531.311/PMM223326.9261.316.114910.03824.7228.212/PMF5912,207441081.850.322835.21,83022.613923.513/PMF3372,74364501.039.544444.02,18047.121850.514/PMF4811,82044.8190.635.91085.23343.4113.2DM/PM (9/5)M/F (7/7)41 +/- 143.2 +/- 3.13,510 +/- 4,18034 +/- 3053 +/- 311.2 +/- 1.032.3 +/- 18.1170.0 +/- 104.818.6 +/- 13.81,121.3 +/- 978.918.1 +/- 19.566.4 +/- 60.622.7 +/- 21.5aThe mRNA expressions were showed by relative levels compared to controls. Muscle tissue sections from three patients with non-specific muscle manifestations but normal histological findings were used as the controls
###end p 13
###begin p 14
###xml 120 128 <span type="species:ncbi:9606">patients</span>
Clinical and laboratory characteristics and the expression of TLR2, TLR4, TLR9, IFNgamma, IL4, IL17, and TNFalpha in 14 patients with DM and PM
###end p 14
###begin p 15
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
aThe mRNA expressions were showed by relative levels compared to controls. Muscle tissue sections from three patients with non-specific muscle manifestations but normal histological findings were used as the controls
###end p 15
###begin title 16
Laboratory assessments
###end title 16
###begin p 17
Serum levels of C-reactive protein (CRP), the erythrocyte sedimentation rate (ESR), and serum aldolase and creatinine kinase (CK) levels were analyzed at the Department of Clinical Chemistry, Pusan National University Hospital.
###end p 17
###begin title 18
Muscle biopsies
###end title 18
###begin p 19
###xml 126 133 <span type="species:ncbi:9606">patient</span>
Biopsy samples were obtained from the vastus lateralis or deltoid muscle with a "semi-open" muscle biopsy technique, with the patient under local anesthesia. The biopsy specimens were immediately frozen in dry ice and isopentane and stored at -70degreesC until analysis.
###end p 19
###begin title 20
Real-time RT-PCR
###end title 20
###begin p 21
###xml 922 923 891 892 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
###xml 625 628 <span type="species:ncbi:11866?0.5863095238095238|species:ncbi:12321?0.21726190476190477">AMV</span>
After biopsy of the muscle tissues from patients with PM or DM, these were immersed immediately in liquid nitrogen. Total RNA was extracted from the frozen muscle biopsies with TRIzol Reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). Each solution containing 1 mug of RNA was heated at 65degreesC for 15 min, and a mixture containing reverse transcriptase was added to the solution. cDNA was transcribed with reaction cycles of 25degreesC for 10 min, 42degreesC for 60 min, 99degreesC for 5 min, and 4degreesC for 5 min. A First Strand cDNA Synthesis Kit for reverse transcription-polymerase chain reaction (RT-PCR; AMV, Roche Applied Science, Indianapolis, IN, USA) was used for the reactions described above, and real-time PCR was performed in a LightCycler System Instrument (Roche Applied Science). LightCycler-DNA Master SYBR Green I (Roche Applied Science), the cDNA template, each primer, and 25 mM of MgCl2 were added to microcapillary tubes to a final volume of 20 mul. The PCR cycling parameters were 50 cycles of denaturation at 95degreesC for 10 s, annealing at 60degreesC for 5 s, and primer extension at 72degreesC for 20 s.
###end p 21
###begin p 22
The primers 5'-GCCACCATTTCCACGGACT-3' (sense) and 5'-GGCTTCCTCTTGGCCTGG-3' (antisense) were used to amplify TLR2, 5'-CTCTGCCTTCACTACA GAGACTTT-3' (sense) and 5'-TGTGGAAGC CTTCCTGGATG-3' (antisense) for TLR4, 5'-ACTGAGCACCCCTGCTTCTA-3' (sense) and 5'-AGATTAGTCACGG CAGGAA-3' (antisense) for TLR9, 5'-TCCCATGGGTTGTGTGTTTA-3' (sense) and 5'-AAGCA CCAGGCATGAAATCT-3' (antisense) for IFNgamma, 5'-ACCCAAACTAGGCCTCACCT-3' (sense) and 5'-ACAGGTGGCATCTTGGAAAC-3' (antisense) for IL4, 5'-TCTCAT CCAGCAAGAGATCC-3' (sense) and 5'-AGTTTGGGACCCCTTTACAC-3' (antisense) for IL17, and 5'-CAAACCACCAAGTGGAGGAG-3' (sense) and 5'-AGATAGCAAATC GGCTGACG-3' (antisense) for TNFalpha, all purchased from Bioneer (Daejun, Korea).
###end p 22
###begin p 23
###xml 21 22 21 22 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 22 23 22 23 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
The threshold cycle (CT) was determined by monitoring the fluorescent signal for each cycle, and the amounts of mRNA in the experimental groups were determined relative to those of the control group.
###end p 23
###begin title 24
Immunohistochemistry for TLR2, TLR4, and TLR9
###end title 24
###begin p 25
###xml 106 107 106 107 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 108 109 108 109 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The cryotissue was fixed in 4% paraformaldehyde, and endogenous peroxidase activity was quenched with 3% H2O2 in methanol. Immunohistochemistry was performed using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA). The tissues were incubated with the primary antibody directed against TLR2 (sc-8689), TLR4 (sc-10741), or TLR9 (sc16247) overnight at 4degreesC. All the primary antibodies were purchased from Santa Cruz Biotechnology, Inc. The slides were incubated with biotinylated secondary antibody solution and then treated with the avidin/biotinylated enzyme complex. The final color product was developed using diaminobenzidine chromogen (Dako, Carpinteria, CA, USA).
###end p 25
###begin title 26
Statistical analysis
###end title 26
###begin p 27
###xml 75 76 75 76 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 96 97 96 97 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Differences between experimental groups were tested using the Mann-Whitney U test and Student's t test, depending on the parameter. The data are expressed as means +/- standard deviations (SD).
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
###xml 104 112 <span type="species:ncbi:9606">patients</span>
The expression levels of TLR2, TLR4, TLR9, IFNgamma, IL4, IL17, and TNFalpha were significantly high in patients with DM and PM compared to controls
###end title 29
###begin p 30
###xml 335 336 309 310 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
The mRNA expression levels of TLR2 (32.3 +/- 18.1), TLR4 (170.0 +/- 104.8), TLR9 (18.6 +/- 13.8), IFNgamma (1121.3 +/- 978.9), IL4 (18.1 +/- 19.5), IL17 (66.4 +/- 60.6), and TNFalpha (22.7 +/- 21.5) were significantly high in patients compared to those of the controls, and the levels of TLR4 and IFNgamma were prominently high (Table 1). These expression levels were not significantly different between PM and DM, and any of these levels did not significantly correlate with disease duration, age, serum level of ESR, CRP, CK, and aldolase.
###end p 30
###begin title 31
The expression levels of TLR4 and TLR9 had significant positive correlations with those of IFNgamma, IL4, IL17, and TNFalpha
###end title 31
###begin p 32
###xml 197 198 185 186 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 232 233 220 221 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 248 249 236 237 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 282 283 270 271 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 299 300 287 288 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 333 334 321 322 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 358 359 342 343 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 376 377 360 361 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 400 401 384 385 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 415 416 399 400 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 419 425 403 409 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 425 759 409 727 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Correlations of TLR2, TLR4, TLR9, IFN&#947;, IL4, L17, and TNF&#945; expressions in patients with DM and PM. The expression levels of TLR4 and TLR9 had significant positive correlations with those of IFN&#947;, IL4, IL17, and TNF&#945;. The mRNA expressions were measured by real-time RT&#8211;PCR from muscle tissues of patients with DM and PM</p>
###xml 425 759 409 727 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Correlations of TLR2, TLR4, TLR9, IFN&#947;, IL4, L17, and TNF&#945; expressions in patients with DM and PM. The expression levels of TLR4 and TLR9 had significant positive correlations with those of IFN&#947;, IL4, IL17, and TNF&#945;. The mRNA expressions were measured by real-time RT&#8211;PCR from muscle tissues of patients with DM and PM</p></caption>
###xml 759 759 727 727 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="10067_2009_1316_Fig1_HTML" id="MO1"/>
###xml 419 759 403 727 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="33">Correlations of TLR2, TLR4, TLR9, IFN&#947;, IL4, L17, and TNF&#945; expressions in patients with DM and PM. The expression levels of TLR4 and TLR9 had significant positive correlations with those of IFN&#947;, IL4, IL17, and TNF&#945;. The mRNA expressions were measured by real-time RT&#8211;PCR from muscle tissues of patients with DM and PM</p></caption><graphic xlink:href="10067_2009_1316_Fig1_HTML" id="MO1"/></fig>
###xml 507 515 <span type="species:ncbi:9606">patients</span>
###xml 736 744 <span type="species:ncbi:9606">patients</span>
The expression levels of TLR2 had no significant correlations with those of IFNgamma, IL4, IL17, and TNFalpha, whereas the levels of TLR4 and TLR9 had positive correlations with those of IFNgamma (r = 0.76 in TLR4 and 0.73 in TLR9, p < 0.01), IL4 (r = 0.8 in TLR4 and 0.76 in TLR9, p < 0.01), IL17 (r = 0.92 in TLR4 and 0.9 in TLR9, p < 0.01), and TNFalpha (r = 0.71 in TLR4, p < 0.01; 0.66 in TLR9, p = 0.01; Fig. 1). Fig. 1Correlations of TLR2, TLR4, TLR9, IFNgamma, IL4, L17, and TNFalpha expressions in patients with DM and PM. The expression levels of TLR4 and TLR9 had significant positive correlations with those of IFNgamma, IL4, IL17, and TNFalpha. The mRNA expressions were measured by real-time RT-PCR from muscle tissues of patients with DM and PM
###end p 32
###begin p 33
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
Correlations of TLR2, TLR4, TLR9, IFNgamma, IL4, L17, and TNFalpha expressions in patients with DM and PM. The expression levels of TLR4 and TLR9 had significant positive correlations with those of IFNgamma, IL4, IL17, and TNFalpha. The mRNA expressions were measured by real-time RT-PCR from muscle tissues of patients with DM and PM
###end p 33
###begin title 34
Immunohistochemistry of TLR2, TLR4, and TLR9
###end title 34
###begin p 35
###xml 150 151 150 151 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 153 154 153 154 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 160 161 160 161 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 164 170 164 170 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 350 352 350 352 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A3</italic>
###xml 430 432 430 432 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A4</italic>
###xml 565 567 565 567 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A1</italic>
###xml 569 570 569 570 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 170 595 170 595 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Immunohistochemistry of TLR2 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR2 was expressed by infiltrating cells in the perimysial area (<italic>A3</italic>), whereas in PM, TLR2 was expressed by infiltrating cells in the endomysium (<italic>A4</italic>). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (<italic>A1</italic>, <italic>2</italic>). Magnification was &#215;400</p>
###xml 170 595 170 595 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Immunohistochemistry of TLR2 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR2 was expressed by infiltrating cells in the perimysial area (<italic>A3</italic>), whereas in PM, TLR2 was expressed by infiltrating cells in the endomysium (<italic>A4</italic>). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (<italic>A1</italic>, <italic>2</italic>). Magnification was &#215;400</p></caption>
###xml 595 595 595 595 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="10067_2009_1316_Fig2_HTML" id="MO2"/>
###xml 164 595 164 595 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="36">Immunohistochemistry of TLR2 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR2 was expressed by infiltrating cells in the perimysial area (<italic>A3</italic>), whereas in PM, TLR2 was expressed by infiltrating cells in the endomysium (<italic>A4</italic>). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (<italic>A1</italic>, <italic>2</italic>). Magnification was &#215;400</p></caption><graphic xlink:href="10067_2009_1316_Fig2_HTML" id="MO2"/></fig>
###xml 595 601 595 601 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 781 783 781 783 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B3</italic>
###xml 861 863 861 863 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B4</italic>
###xml 996 998 996 998 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B1</italic>
###xml 1000 1001 1000 1001 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 601 1026 601 1026 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">Immunohistochemistry of TLR4 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR4 was expressed by infiltrating cells in the perimysial area (<italic>B3</italic>), whereas in PM, TLR4 was expressed by infiltrating cells in the endomysium (<italic>B4</italic>). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (<italic>B1</italic>, <italic>2</italic>). Magnification was &#215;400</p>
###xml 601 1026 601 1026 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">Immunohistochemistry of TLR4 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR4 was expressed by infiltrating cells in the perimysial area (<italic>B3</italic>), whereas in PM, TLR4 was expressed by infiltrating cells in the endomysium (<italic>B4</italic>). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (<italic>B1</italic>, <italic>2</italic>). Magnification was &#215;400</p></caption>
###xml 1026 1026 1026 1026 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="10067_2009_1316_Fig3_HTML" id="MO3"/>
###xml 595 1026 595 1026 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="37">Immunohistochemistry of TLR4 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR4 was expressed by infiltrating cells in the perimysial area (<italic>B3</italic>), whereas in PM, TLR4 was expressed by infiltrating cells in the endomysium (<italic>B4</italic>). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (<italic>B1</italic>, <italic>2</italic>). Magnification was &#215;400</p></caption><graphic xlink:href="10067_2009_1316_Fig3_HTML" id="MO3"/></fig>
###xml 1026 1032 1026 1032 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 1219 1221 1219 1221 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C3</italic>
###xml 1299 1301 1299 1301 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C4</italic>
###xml 1434 1436 1434 1436 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C1</italic>
###xml 1438 1439 1438 1439 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1032 1464 1032 1464 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="38">Immunohistochemistry of TLR9 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR9 was weakly expressed by infiltrating cells in the perimysial area (<italic>C3</italic>), whereas in PM, TLR9 was expressed by infiltrating cells in the endomysium (<italic>C4</italic>). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (<italic>C1</italic>, <italic>2</italic>). Magnification was &#215;400</p>
###xml 1032 1464 1032 1464 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38">Immunohistochemistry of TLR9 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR9 was weakly expressed by infiltrating cells in the perimysial area (<italic>C3</italic>), whereas in PM, TLR9 was expressed by infiltrating cells in the endomysium (<italic>C4</italic>). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (<italic>C1</italic>, <italic>2</italic>). Magnification was &#215;400</p></caption>
###xml 1464 1464 1464 1464 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="10067_2009_1316_Fig4_HTML" id="MO4"/>
###xml 1026 1464 1026 1464 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="38">Immunohistochemistry of TLR9 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR9 was weakly expressed by infiltrating cells in the perimysial area (<italic>C3</italic>), whereas in PM, TLR9 was expressed by infiltrating cells in the endomysium (<italic>C4</italic>). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (<italic>C1</italic>, <italic>2</italic>). Magnification was &#215;400</p></caption><graphic xlink:href="10067_2009_1316_Fig4_HTML" id="MO4"/></fig>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
###xml 908 916 <span type="species:ncbi:9606">patients</span>
###xml 1082 1090 <span type="species:ncbi:9606">patients</span>
###xml 1346 1354 <span type="species:ncbi:9606">patients</span>
TLR2, TLR4, and TLR9 were expressed by perimysial infiltrating cells in DM, whereas they were expressed by endomysial infiltrating cells in PM (Figs. 2, 3, and 4). Fig. 2Immunohistochemistry of TLR2 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR2 was expressed by infiltrating cells in the perimysial area (A3), whereas in PM, TLR2 was expressed by infiltrating cells in the endomysium (A4). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (A1, 2). Magnification was x400Fig. 3Immunohistochemistry of TLR4 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR4 was expressed by infiltrating cells in the perimysial area (B3), whereas in PM, TLR4 was expressed by infiltrating cells in the endomysium (B4). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (B1, 2). Magnification was x400Fig. 4Immunohistochemistry of TLR9 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR9 was weakly expressed by infiltrating cells in the perimysial area (C3), whereas in PM, TLR9 was expressed by infiltrating cells in the endomysium (C4). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (C1, 2). Magnification was x400
###end p 35
###begin p 36
###xml 180 182 180 182 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A3</italic>
###xml 260 262 260 262 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A4</italic>
###xml 395 397 395 397 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A1</italic>
###xml 399 400 399 400 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
Immunohistochemistry of TLR2 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR2 was expressed by infiltrating cells in the perimysial area (A3), whereas in PM, TLR2 was expressed by infiltrating cells in the endomysium (A4). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (A1, 2). Magnification was x400
###end p 36
###begin p 37
###xml 180 182 180 182 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B3</italic>
###xml 260 262 260 262 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B4</italic>
###xml 395 397 395 397 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B1</italic>
###xml 399 400 399 400 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
Immunohistochemistry of TLR4 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR4 was expressed by infiltrating cells in the perimysial area (B3), whereas in PM, TLR4 was expressed by infiltrating cells in the endomysium (B4). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (B1, 2). Magnification was x400
###end p 37
###begin p 38
###xml 187 189 187 189 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C3</italic>
###xml 267 269 267 269 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C4</italic>
###xml 402 404 402 404 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C1</italic>
###xml 406 407 406 407 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
Immunohistochemistry of TLR9 in muscle tissues of patients with DM, PM, and controls. In the muscle tissues of DM, TLR9 was weakly expressed by infiltrating cells in the perimysial area (C3), whereas in PM, TLR9 was expressed by infiltrating cells in the endomysium (C4). Control muscle tissues were obtained from patients with non-specific muscle manifestations but with normal histological findings (C1, 2). Magnification was x400
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 302 304 302 304 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 101 106 <span type="species:ncbi:9606">human</span>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 572 580 <span type="species:ncbi:9606">patients</span>
Data originating predominantly from animal models of autoimmune disease and circumstantial data from human patients suggest that the inappropriate activation of the TLR pathway by endogenous or exogenous ligands may lead to the initiation and/or perpetuation of autoimmune responses and tissue injury [24]. The expression of TLRs by both immune cells and the resident cells in the involved tissues supports their important roles in tissue injury, destruction, and repair. We showed that the expression levels of TLR2, TLR4, and TLR9 were elevated in the muscle tissues of patients with DM and PM compared to controls, and as far as we know, this is the first report of this phenomenon in DM and PM.
###end p 40
###begin p 41
###xml 173 175 169 171 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
We reported that inflammatory cytokines such as IL17, TNFalpha, IL1, and IL6 increase the production of TLR2, TLR4, and TLR9 from mice synoviocytes in autoimmune arthritis [25]. The possible mechanisms of TLR overexpressions are as follows: (1) various microbial pathogens considered as etiologic agents of IIMs contribute to overexpressions; (2) endogenous molecules and cytokines that are generated during muscle damage or immune response induce the overexpressions.
###end p 41
###begin p 42
###xml 206 207 206 207 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 383 384 383 384 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 504 505 504 505 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 559 560 559 560 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
DM is a microangiopathy affecting the skin and muscle, in which the early activation and deposition of complement causes the lysis of endomysial capillaries and muscle ischemia. In PM, clonally expanded CD8+ cytotoxic T cells invade muscle fibers that express MHC class I antigens, leading to fiber necrosis via the perforin pathway. Perimysial and perivascular inflammation with CD4+ T cell, B cells, and macrophage infiltrations are histological features of DM, whereas endomysial inflammation with CD8+ T-cell infiltration is a histological feature of PM [1]. We have demonstrated that TLR2, TLR4, and TLR9 are expressed by perimysial infiltrating cells in DM and by endomysial infiltrating cells in PM. These expression patterns of TLR2, TLR4, and TLR9 were consistent with the histopathological features of DM and PM.
###end p 42
###begin p 43
###xml 3 4 3 4 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 60 61 60 61 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 183 184 179 180 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 391 392 387 388 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 478 479 474 475 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 684 685 676 677 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 596 604 <span type="species:ncbi:9606">patients</span>
CD4+ T cells play roles in immunopathogenesis of DM and PM [7]. Detection of IFNgamma and IL17 producing cells in muscle tissues of DM and PM suggests the involvement of activated CD4+ T cells in the pathophysiology of both DM and PM. These data showed that non-specific amplification of muscle inflammation by T lymphocytes may result from the local production of cytokines and chemokines [8]. We have demonstrated that the expressions of cytokines that are associated with CD4+ T-cell activation including IFNgamma (Th1 cytokine), IL4 (Th2 cytokine), and IL17 (Th17 cytokine) were increased in patients with DM and PM compared to controls. These results imply that activation of CD4+ T cells is involved in immunopathogenesis of DM and PM.
###end p 43
###begin p 44
###xml 146 147 146 147 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 301 302 301 302 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 312 314 312 314 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 320 321 320 321 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 515 516 511 512 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 517 518 513 514 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 563 564 559 560 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 718 720 714 716 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 721 723 717 719 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
TLR signaling may promote autoimmunity by several mechanisms. TLR signaling of B lymphocytes enhance their antigen-presenting capacity towards CD4+ T cells through up-regulation of HLA-DR. TLR signaling in plasmacytoid DCs results in maturation of DCs, and mature DCs promote induced activation of CD4+ T cells [24]. CD4+ T cells are categorized as Th1, Th2, or Th17 cells, and the function of these cells is to produce reciprocal sets of cytokines: IFNgamma by Th1 cells, IL4 by Th2 cells, and IL17 by Th17 cells [4-6]. Specific TLRs might be associated with CD4+ T-cell activation. Activation of TLR2 might induce Th2 immune response, TLR4 induced Th1 and Th17 immune response, and TLR9 induced Th1 immune response [14-21]. We showed that the expression levels of TLR4 and TLR9 were increased compared to controls and had significant positive correlations with those of IFNgamma, IL4, and IL17. These results suggest that the overexpression of TLR4 and TLR9 might be involved in the immunopathogenesis of DM and PM through activation of Th1, Th2, and Th17 cells. And the data showed by our study that the expression levels of TLR4 and IFNgamma were prominently high and had significantly positive correlations with each other suggest that TLR4-induced Th1 response might play a more important role in immunopathogenesis of DM and PM.
###end p 44
###begin p 45
###xml 91 93 87 89 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 94 96 90 92 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 547 549 531 533 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 551 553 535 537 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 717 725 <span type="species:ncbi:9606">patients</span>
TNFalpha gene expression can be detected in the muscle tissues of most patients with IIMs [26-28]. TNFalpha acts via several possible mechanisms, including the positive feedback loop in which increased numbers of TNFalpha-producing cells in infiltrating cell clusters enhance the inflammatory reaction by releasing more TNFalpha. This mediates the upregulation of adhesion molecules on endothelial cells and hence increases transendothelial cell trafficking as well as enhancing the T-cell response and thereby also T-cell-mediated muscle injury [29, 30]. We have showed that the expression level of TNFalpha was elevated and had significant positive correlations with those of TLR4 and TLR9 in the muscle tissues of patients with DM and PM.
###end p 45
###begin p 46
###xml 146 147 146 147 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 320 321 320 321 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 413 414 409 410 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 572 573 568 569 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
According to recent studies, including our previous reported study and our present data, the possible immunopathogenic involvement of TLRs and CD4+ T cells are as follows: (1) overexpression of TLR4 and TLR9 induced by microbial pathogen, endogenous molecules, and inflammatory cytokines contributed to activation of CD4+ T cells resulting in increased expression of IFNgamma, IL4, and IL17; (2) overexpressed CD4+ T-cell cytokines induce the inflammatory response, resulting in an increase of various inflammatory cytokines and endogenous molecules; (3) overexpressed CD4+ T-cell and inflammatory cytokines, including IFNgamma, IL4, IL17, and TNFalpha, and endogenous molecules induce the overexpression of TLRs, causing the vicious cycle of amplification of chronic inflammation in muscle tissues of DM and PM.
###end p 46
###begin p 47
###xml 502 503 502 503 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
In conclusion, we have demonstrated that the expressions of TLR2, TLR4, and TLR9 were elevated in muscle tissue of patients with DM and PM, and their expression patterns were consistent with pathophysiology of DM and PM. We also showed that the expression levels of TLR4 and TLR9 had significant positive correlations with those of Th1, Th2, and Th17 cell cytokines. These results suggest that the involvement of TLR4 and 9 in the immunopathogenesis of DM and PM may be connected with activation of CD4+ T cells.
###end p 47
###begin p 48
This work was supported by a grant (R11-2002-098-05001-0) from the Korea Science and Engineering Foundation through the Rheumatism Research Center (RhRC) at the Catholic University of Korea and by a project grant from Pusan National University Hospital Institute.
###end p 48
###begin p 49
###xml 0 11 0 11 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Disclosures</bold>
Disclosures None
###end p 49
###begin p 50
###xml 0 11 0 11 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 50
###begin title 51
References
###end title 51
###begin article-title 52
Polymyositis and dermatomyositis
###end article-title 52
###begin article-title 53
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Increased expression of interleukin 1 alpha and MHC class I in muscle tissue of patients with chronic inactive polymyositis and dermatomyositis
###end article-title 53
###begin article-title 54
Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells
###end article-title 54
###begin article-title 55
Th1/Th2 cells in inflammatory disease states: therapeutic implications
###end article-title 55
###begin article-title 56
Origins of the T(H)1-T(H)2 model: a personal perspective
###end article-title 56
###begin article-title 57
Differentiation and function of Th17 T cells
###end article-title 57
###begin article-title 58
Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies
###end article-title 58
###begin article-title 59
Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells
###end article-title 59
###begin article-title 60
Cytokines in idiopathic inflammatory myopathies
###end article-title 60
###begin article-title 61
Pathogen recognition and innate immunity
###end article-title 61
###begin article-title 62
Receptor-mediated monitoring of tissue well-being via detection of soluble heparin sulfate by Toll-like receptor 4
###end article-title 62
###begin article-title 63
The extra domain A of fibronection activates Toll-like receptor 4
###end article-title 63
###begin article-title 64
The matrix component bigylcan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages
###end article-title 64
###begin article-title 65
###xml 62 67 <span type="species:ncbi:9606">human</span>
Toll-like receptor 2 (TLR2) and TLR4 differentially activated human dendritic cells
###end article-title 65
###begin article-title 66
CpG motifs in bacterial DNA and their immune effects
###end article-title 66
###begin article-title 67
In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas
###end article-title 67
###begin article-title 68
Interleukin-12 and the regulation of innate resistance and adaptive immunity
###end article-title 68
###begin article-title 69
Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos
###end article-title 69
###begin article-title 70
A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells
###end article-title 70
###begin article-title 71
Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma
###end article-title 71
###begin article-title 72
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis
###end article-title 72
###begin article-title 73
Polymyositis and dermatomyositis (first part)
###end article-title 73
###begin article-title 74
Polymyositis and dermatomyositis (second part)
###end article-title 74
###begin article-title 75
Toll-like receptors and autoimmunity: a critical appraisal
###end article-title 75
###begin article-title 76
IL17 increases the expression of Toll-like receptor-2, 4, and 9 by increasing IL-1 and IL-6 production in autoimmune arthritis
###end article-title 76
###begin article-title 77
Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls
###end article-title 77
###begin article-title 78
Local T-cell proliferation and differentiation in inflammatory myopathies
###end article-title 78
###begin article-title 79
Expression of tumor necrosis factor-alpha in muscles of polymyositis
###end article-title 79
###begin article-title 80
###xml 114 115 114 115 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 51 57 <span type="species:ncbi:10090">murine</span>
###xml 98 115 <span type="species:ncbi:12072">coxsackievirus B3</span>
Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3
###end article-title 80
###begin article-title 81
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 112 117 <span type="species:ncbi:9606">human</span>
Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses
###end article-title 81
###begin p 82
Geun-Tae Kim and Mi-La Cho are co-first authors.
###end p 82

